|
SH3PXD2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.51369982793437E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.51879999968452E-07 |
| Normal-vs-Stage2 |
4.543800E-03 |
| Normal-vs-Stage3 |
6.35089999999616E-05 |
| Normal-vs-Stage4 |
3.72980000000744E-05 |
| Stage1-vs-Stage2 |
7.109000E-01 |
| Stage1-vs-Stage3 |
4.677400E-01 |
| Stage1-vs-Stage4 |
3.336300E-02 |
| Stage2-vs-Stage3 |
8.834800E-01 |
| Stage2-vs-Stage4 |
1.521990E-01 |
| Stage3-vs-Stage4 |
1.216200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.74050046281616E-10 |
| Normal-vs-AfricanAmerican |
3.395600E-02 |
| Normal-vs-Asian |
7.606000E-04 |
| Caucasian-vs-AfricanAmerican |
7.416600E-01 |
| Caucasian-vs-Asian |
3.446000E-01 |
| AfricanAmerican-vs-Asian |
4.869000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.591180E-04 |
| Normal-vs-Female |
9.89999970890665E-10 |
| Male-vs-Female |
6.112000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.21679999976321E-07 |
| Normal-vs-Age(41-60Yrs) |
3.65049999995204E-06 |
| Normal-vs-Age(61-80Yrs) |
9.76449999999796E-05 |
| Normal-vs-Age(81-100Yrs) |
7.078200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.499800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.149400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.024000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.662200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.765600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.545600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.824000E-01 |
| Classical-VS-Follicular |
9.361700E-02 |
| Classical-VS-Other |
4.376100E-03 |
| Classical-VS-Normal |
3.04460012756635E-10 |
| Tall-VS-Follicular |
5.776100E-02 |
| Tall-VS-Other |
3.297400E-03 |
| Tall-VS-Normal |
3.416500E-04 |
| Follicular-VS-Other |
8.621800E-02 |
| Follicular-VS-Normal |
5.397100E-03 |
| Other-VS-Normal |
7.715200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.34349999999051E-05 |
| Normal-vs-N1 |
2.785500E-04 |
| N0-vs-N1 |
9.331600E-02 |
|
|
